Inactivation of Chikungunya virus by 1,5 iodonapthyl azide

Virology Journal

Volumn 9, Issue , 2012, Pages

  Sharma, Anuj ^a   Gupta, Paridhi ^a,b   Maheshwari, Radha K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Chikungunya virus; Inactivated vaccine; Iodonapthyl azide

Indexed keywords

1,5 IODONAPTHYL AZIDE; AZIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CHIKUNGUNYA ALPHAVIRUS; CONCENTRATION (PARAMETERS); CYTOPATHOGENIC EFFECT; NONHUMAN; ULTRAVIOLET IRRADIATION; VIRUS INACTIVATION; VIRUS REPLICATION; VIRUS VIRULENCE; WESTERN BLOTTING;

ANIMALS; AZIDES; CELL LINE; CHIKUNGUNYA VIRUS; CRICETINAE; CYTOPATHOGENIC EFFECT, VIRAL; RNA, VIRAL; VIRUS INACTIVATION;

ALPHAVIRUS; ARTHROPODA; CHIKUNGUNYA VIRUS; TOGAVIRIDAE;

EID: 84870364153     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-301     Document Type: Article

References (19)

1. Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Sharma A, Raviv Y, Puri A, Viard M, Blumenthal R, Maheshwari RK, Biochem Biophys Res Commun 2007 358 392 398 10.1016/j.bbrc.2007. 04.115 17493582 (Pubitemid 46755721)
2. Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development. Sharma A, Gupta P, Glass PJ, Parker MD, Maheshwari RK, Vaccine 2011 29 953 959 10.1016/j.vaccine.2010. 11.033 21115048
3. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Das T, Jaffar-Bandjee MC, Hoarau JJ, Krejbich Trotot P, Denizot M, Lee-Pat-Yuen G, Sahoo R, Guiraud P, Ramful D, Robin S, Alessandri JL, Gauzere BA, Gasque P, Prog Neurobiol 2010 91 121 129 10.1016/j.pneurobio.2009.12.006 20026374
4. Dengue and chikungunya infections in travelers. Chen LH, Wilson ME, Curr Opin Infect Dis 2010 23 438 444 10.1097/QCO.0b013e32833c1d16 20581669
5. A single mutation in chikungunya virus affects vector specificity and epidemic potential. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S, PLoS Pathog 2007 3 201 10.1371/journal.ppat.0030201 18069894
6. Differential responses of the mosquito Aedes albopictus from the Indian Ocean region to two chikungunya isolates. Martin E, Moutailler S, Madec Y, Failloux AB, BMC Ecol 2010 10 8 10.1186/1472-6785-10-8
7. Chikungunya fever: a re-emerging viral infection. Chhabra M, Mittal V, Bhattacharya D, Rana U, Lal S, Indian J Med Microbiol 2008 26 5 12 10.4103/0255-0857.38850 18227590 (Pubitemid 351197554)
8. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA, AmJTrop Med Hyg 2000 62 681 685 (Pubitemid 32281485)
9. Chimeric alphavirus vaccine candidates for chikungunya. Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I, Weaver SC, Vaccine 2008 26 5030 5039 10.1016/j.vaccine.2008.07.054 18692107
10. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ, Nat Med 2010 16 334 338 10.1038/nm.2105 20111039
11. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV, Vaccine 2009 27 2513 2522 10.1016/j.vaccine.2009.02.062 19368794
12. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, Wu L, Khan A, Sardesai N, Kim JJ, Vijayachari P, Weiner DB, Vaccine 2008 26 5128 5134 10.1016/j.vaccine.2008.03.060 18471943
13. Prophylaxis and therapy for Chikungunya virus infection. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M, J Infect Dis 2009 200 516 523 10.1086/600381 19572805
14. 5-[125I]Iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Bercovici T, Gitler C, Biochemistry 1978 17 1484 1489 10.1021/bi00601a020 148291 (Pubitemid 8330385)
15. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. Raviv Y, Viard M, Bess JW Jr, Chertova E, Blumenthal R, J Virol 2005 79 12394 12400 10.1128/JVI.79.19.12394-12400.2005 16160166 (Pubitemid 41346101)
16. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Viard M, Aitichou M, Chi X, Ibrahim S, Blumenthal R, Raviv Y, Bavari S, Aman MJ, J Infect Dis 2007 196 Suppl 2 276 S283 17940961
17. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M, J Virol 2008 82 4612 4619 10.1128/JVI.02233-07 18305038 (Pubitemid 351563697)
18. Photochemical Inactivation of Alpha- and Poxviruses. Sagripanti J, Marschall H, Voss L, Hülseweh B, Photochem Photobiol 2003 87 6 1369 1378
19. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Kumar M, Arankalle VA, Vaccine 2012 30 6142 6149 10.1016/j.vaccine.2012.07.072 22884660